<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>                  The safety and efficacy of once daily use of ZIANA Gel for treatment of acne vulgaris were assessed in three 12-week prospective, multi-center, randomized, blinded studies in patients 12 years and older. Studies 1 and 2 were of identical design, and compared ZIANA Gel to clindamycin in the vehicle gel, tretinoin in the vehicle gel, and the vehicle gel alone. Patients with mild, moderate, or severe acne were enrolled in the studies. The co-primary efficacy variables were:<BR>                  <BR>                     <BR>                        (1)Mean percent change from baseline at Week 12 in<BR>								<BR>                           inflammatory lesion counts,<BR>                           non-inflammatory lesion counts, and<BR>                           total lesion counts<BR>                        <BR>                     <BR>                     <BR>                        (2)Percent of subjects who cleared or almost cleared at Week 12 as judged by an Evaluator's Global Severity (EGS) score.<BR>                  <BR>                  The EGS scoring scale used in all of the clinical trials for ZIANA Gel is as follows:<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%"><BR>                     <col width="20%" align="left" valign="top"/><BR>                     <col width="80%" align="left" valign="top"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule">Grade</th><BR>                           <th styleCode="Lrule Rrule">Description</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Clear</td><BR>                           <td styleCode="Lrule Rrule">Normal, clear skin with no evidence of acne vulgaris</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Almost Clear</td><BR>                           <td styleCode="Lrule Rrule">Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Mild</td><BR>                           <td styleCode="Lrule Rrule">Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulocystic lesions)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Moderate</td><BR>                           <td styleCode="Lrule Rrule">Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one small nodulo-cystic  lesion</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Severe</td><BR>                           <td styleCode="Lrule Rrule">Inflammatory lesions are more apparent many comedones and papules/pustules, there may or may not be a few nodulocystic lesions</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule">Very Severe</td><BR>                           <td styleCode="Lrule Rrule">Highly inflammatory lesions predominate, variable number of comedones, many papules/pustules and many nodulocystic lesions</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>In Study 1, a total of 1,252 patients were enrolled, and in Study 2, a total of 1,288 patients were enrolled. The combined results are presented in Table 3.<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%" ID="T3"><BR>                     <caption>Table 3: Efficacy Results at Week 12 in Studies 1 and 2.</caption><BR>                     <col width="40%" align="left" valign="middle"/><BR>                     <col width="15%" align="center" valign="middle"/><BR>                     <col width="15%" align="center" valign="middle"/><BR>                     <col width="15%" align="center" valign="middle"/><BR>                     <col width="15%" align="center" valign="middle"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule"/><BR>                           <th styleCode="Lrule">ZIANA Gel<br/>N=845</th><BR>                           <th styleCode="Lrule">Clindamycin<br/>N=426</th><BR>                           <th styleCode="Lrule">Tretinoin<br/>N=846</th><BR>                           <th styleCode="Lrule Rrule">Vehicle<br/>N=423</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="5" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Evaluator's Global Severity: N (%)</content><BR>                           </td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Patients achieving success<footnote>Success was defined as cleared or almost cleared at Week 12.</footnote><BR>                           </td><BR>                           <td styleCode="Lrule" valign="top">180 (21%)</td><BR>                           <td styleCode="Lrule" valign="top">70 (16%)</td><BR>                           <td styleCode="Lrule" valign="top">122 (14%)</td><BR>                           <td styleCode="Lrule Rrule" valign="top">34 (8%)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="5" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Inflammatory Lesion Count (% reduction from baseline)</content><BR>                           </td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">&#160;&#160;Mean</td><BR>                           <td styleCode="Lrule">48%</td><BR>                           <td styleCode="Lrule">42%</td><BR>                           <td styleCode="Lrule">39%</td><BR>                           <td styleCode="Lrule Rrule">26%</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="5" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Non-inflammatory Lesion Count (% reduction from baseline)</content><BR>                           </td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">&#160;&#160;Mean</td><BR>                           <td styleCode="Lrule">36%</td><BR>                           <td styleCode="Lrule">27%</td><BR>                           <td styleCode="Lrule">31%</td><BR>                           <td styleCode="Lrule Rrule">16%</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="5" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Total Lesion Count (% reduction from baseline)</content><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule">&#160;&#160;Mean</td><BR>                           <td styleCode="Lrule">41%</td><BR>                           <td styleCode="Lrule">34%</td><BR>                           <td styleCode="Lrule">34%</td><BR>                           <td styleCode="Lrule Rrule">20%</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>In Study 3, ZIANA Gel was compared to clindamycin gel in a total of 2,010 patients with moderate or severe acne vulgaris (see Table 3) . As with Studies 1 and 2, the co-primary endpoints were mean percent reduction in lesion counts (inflammatory, non-inflammatory and total) and the Evaluator's Global Severity score. In Study 3, success on the EGS score was assessed by the percentage of subjects who had at least 2 grades of improvement from Baseline to Week 12.<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%"><BR>                     <caption>Table 4: Efficacy Results at Week 12 in Study 3</caption><BR>                     <col width="40%" align="left" valign="top"/><BR>                     <col width="30%" align="center" valign="top"/><BR>                     <col width="30%" align="center" valign="top"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule"/><BR>                           <th styleCode="Lrule">ZIANA Gel<br/>N = 1008</th><BR>                           <th styleCode="Lrule Rrule">Clindamycin<br/>N = 1002</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="3" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Evaluator's Global Severity: N (%)</content><BR>                           </td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Patients achieving success<footnote>Success was defined as at least a 2-grade improvement at Week 12 from baseline.</footnote><BR>                           </td><BR>                           <td styleCode="Lrule" valign="top">415 (41%)</td><BR>                           <td styleCode="Lrule Rrule" valign="top">345 (34%)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="3" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Inflammatory Lesion Count (% reduction from baseline)</content><BR>                           </td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Mean</td><BR>                           <td styleCode="Lrule">61%</td><BR>                           <td styleCode="Lrule Rrule">55%</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="3" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Non-inflammatory Lesion Count (% reduction from baseline)</content><BR>                           </td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule">Mean</td><BR>                           <td styleCode="Lrule">50%</td><BR>                           <td styleCode="Lrule Rrule">41%</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td colspan="3" styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Total Lesion Count (% reduction from baseline)</content><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule">Mean</td><BR>                           <td styleCode="Lrule">54%</td><BR>                           <td styleCode="Lrule Rrule">47%</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>               <BR><BR><BR><BR>               <BR>            <BR>         </P></DIV></HTML>